French diagnostics firm Ipsogen said this week that it has signed an agreement with DNAVision, a Belgian pharmacogenomics lab that caters to biotech and pharmaceutical customers, to provide a series of array-based microarray tests for breast cancer that it plans to launch next year.
 
The agreement follows Ipsogen’s announcement last week that it has become a Powered by Affymetrix partner company, which gives it the right to market its breast cancer tests on Affy’s GeneChip microarray platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.